Table of Content - Interstitial Lung Disease Market

Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:

Shortness of breath at rest
Dry cough

The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study

This report provides an in-depth analysis of global interstitial lung disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global interstitial lung disease market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.

Market Segmentation

By Disease Type (Revenue, USD Bn, 2021-2033)
- Interstitial Pneumonia
- Idiopathic Pulmonary Fibrosis
- Nonspecific Interstitial Pneumonitis
- Hypersensitivity Pneumonitis
- Cryptogenic Organizing Pneumonia (COP)
- Sarcoidosis
- Acute Interstitial Pneumonitis
By Drug Type (Revenue, USD Bn, 2021-2033)
- Corticosteroids
- Anti-fibrotic Medication
- Pirfenidone
- Nintedanib
By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Interstitial Lung Disease Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa
Key Players
- MSD (Merck)
- Liminal Biosciences
- Glenmark Pharma
- Chemicals & Pharmaceuticals
- Boehringer Ingelhim International GmbH
- Hoffmann-La Roche Ltd.
- Cipla

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Overview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Disease Type
  - Market Snapshot, By Drug Type
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Disease Type Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter’s Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
Global Interstitial Lung Disease Market, By Disease Type, 2021 – 2033, (USD Billion)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022– 2033
  - Segment Trends
- Interstitial Pneumonia
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Idiopathic Pulmonary Fibrosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Nonspecific Interstitial Pneumonitis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Hypersensitivity Pneumonitis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Cryptogenic Organizing Pneumonia (COP)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Sarcoidosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Acute Interstitial Pneumonitis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Global Interstitial Lung Disease Market, By Drug Type, 2021 – 2033, (USD Billion)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022– 2033
  - Segment Trends
- Corticosteroids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Anti-fibrotic Medication
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Pirfenidone
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Nintedanib
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Global Interstitial Lung Disease Market, By Distribution Channel, 2021 – 2033, (USD Billion)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022– 2033
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Global Interstitial Lung Disease Market, By Region, 2021 – 2033, (USD Billion)
- Introduction
  - Market Share Analysis, By Region, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, For Regions, 2022–2033
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
  - MSD (Merck)
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Liminal Biosciences
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Glenmark Pharma
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - B. Chemicals & Pharmaceuticals
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Boehringer Ingelhim International GmbH
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - F. Hoffmann-La Roche Ltd.
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
  - Cipla
    - Company Highlights
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Market Strategies
- Analyst Views
Section
- References
- Research Methodology
- About Us

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE